AI Partnership Drive: Social media observers highlight Novo Nordisk's broad alliance with OpenAI to embed artificial intelligence throughout drug discovery, manufacturing, and supply chain operations. The move follows a reported 16% stock decline as the company trails Eli Lilly in key markets. Full implementation is slated for completion by the end of 2026.
Strategic Catch-Up Efforts: Analysts on social media describe the initiative as an essential response to competitive pressures, with AI expected to speed up candidate identification and workforce upskilling for 68,000 employees. Discussions emphasize potential efficiency gains in the pharma sector valued at tens of billions annually. Participants view the step as a necessary evolution rather than a passing trend.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Revenue
Novo Nordisk had revenues of $15B in Q1 2026.
You can track NVO financials on Quiver Quantitative's NVO stock page.
You can access data on NVO stock through the Quiver Quantitative API.
Novo Nordisk Hedge Fund Activity
We have seen 564 institutional investors add shares of Novo Nordisk stock to their portfolio, and 902 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX added 19,333,750 shares (+inf%) to their portfolio in Q1 2026, for an estimated $693,211,606
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 9,884,077 shares (+808.8%) to their portfolio in Q1 2026, for an estimated $354,393,580
- FMR LLC removed 8,664,705 shares (-86.5%) from their portfolio in Q1 2026, for an estimated $310,672,997
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 7,827,491 shares (+inf%) to their portfolio in Q1 2026, for an estimated $280,654,689
- TWO SIGMA INVESTMENTS, LP added 5,943,310 shares (+1731.8%) to their portfolio in Q1 2026, for an estimated $213,097,380
- GOLDMAN SACHS GROUP INC removed 5,865,741 shares (-53.4%) from their portfolio in Q1 2026, for an estimated $210,316,143
- BOSTON PARTNERS removed 5,231,804 shares (-97.3%) from their portfolio in Q1 2026, for an estimated $187,586,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 11/28/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 3 analysts offer price targets for $NVO in the last 6 months, with a median target of $46.0.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
- Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
